Invivyd Says Updated NCCN Guidelines For Prevention And Treatment Of Cancer-Related Infections Now Recommend Use Of Available Monoclonal Antibodies For Pre-Exposure Prophylaxis Of COVID-19

• NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer populations
• Reflects growing alignment among NCCN, IDSA, and CDC on the role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19
• New data published online in JAMA Oncology from the National Cancer Institute COVID-19 in Cancer Patients Study showed COVID-19 had a significant impact on cancer patients, including serious delays or even cessation of cancer treatment and prolonged complications
   

WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), today announced the June 20, 2025 updated National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Prevention and Treatment of Cancer-Related Infections now recommend the use of available monoclonal antibodies for pre-exposure prophylaxis of COVID-19. The NCCN Guidelines advise clinicians to refer to guidance from Infectious Diseases Society of America (IDSA), Centers for Disease Control and Prevention (CDC), or U.S. Food and Drug Administration for available monoclonal antibody options. This recommendation reflects the growing alignment among key organizations - including IDSA and CDC - reinforcing the critical role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19.

New research titled Risk Factors for COVID-19–Related Hospitalization and Death in Patients With Cancer published online on July 17, 2025 in JAMA Oncology reflects why prevention of SARS-CoV-2 is important for people with cancer. The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) provides critical insights into the long-term impact of SARS-CoV-2 infection in these individuals.

Over a two-year period, the NCCAPS study followed 1,572 eligible adult patients with cancer who also had COVID-19. The data revealed high risk of severe disease as evidenced by the rate of hospitalization, treatment delays, and mortality within 90 days among patients undergoing chemotherapy or those with hematologic malignancies, consistent with previous studies. Notably, of the 290 patients that were initially hospitalized for COVID-19, 31 patients had a second admission for sequelae of COVID-19 within 30 days of their initial admission. Over 50% of all cancer treatment disruptions in the cohort were directly attributed to COVID-19, especially during the early phase of infection. These disruptions raised concerns about continuity of care and long-term impacts on patient outcomes. These data highlight the importance of continued surveillance and prevention strategies in populations at highest risk for COVID-19 complications.